Moreover, in another prospective cohort study performed by Gust et al., which included 43 patients aged 1 to 25 who received CD19-directed CAR-T cells for ALL, no statistically significant differences in the levels of VEGF-A, ANG-1, ANG-2, or ANG-2: ANG-1 ratio were observed between patients with neurotoxicity (n = 19) and those without (n = 24) [52]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.